Ted Kramm Appointed To BioMatrix Specialty Pharmacy Board Of Directors
Board Addition Will Accelerate Growth And Expand Expertise in Specialty Infusion Services
"We are excited to welcome
Kramm most recently served as Chief Executive Officer of Molecular Designs, a leader in the molecular diagnostic industry. Prior to that he was the co-founder and Chief Executive Officer of AxelaCare Health Solutions and Vice President of Operations at US BioServices. He has more than 30 years of experience in building successful home infusion and specialty pharmacy companies. Kramm is a pharmacist and holds a bachelor's degree from Philadelphia College of Pharmacy, now part of
About BioMatrix Specialty Pharmacy
BioMatrix is a nationwide, independently owned specialty infusion pharmacy with decades of experience in specialty infusion and a compassionate care team that helps patients navigate the often-challenging healthcare environment. The company has been recognized on the INC 5000 list of fastest growing companies in America, recognized by The National Association for Business Resources (NABR) as a "Best & Brightest Company to Work For in the Nation" from 2019 to 2023, and carries several industry leading healthcare accreditations. To view current BioMatrix career opportunities visit: https://bit.ly/3JMpAU6
Media Contact: Tara Marchese
Senior Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ted-kramm-appointed-to-biomatrix-specialty-pharmacy-board-of-directors-302027890.html
SOURCE BioMatrix Specialty Pharmacy
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Return to growth following a successful strategic reset
- Questcorp Mining Completes Acquisition of 100% Interest in North Island Copper Project
- Blue Moon Announces Sale of Blue Moon Norway to ACG Metals Limited
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share